American Renal Associates Holdings Inc. (NYSE:ARA)’s share price was down 3.9% on Wednesday . The stock traded as low as $22.65 and last traded at $22.68, with a volume of 61,179 shares. The stock had previously closed at $23.59.

Several equities analysts have recently weighed in on ARA shares. Zacks Investment Research cut shares of American Renal Associates Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Leerink Swann started coverage on shares of American Renal Associates Holdings in a research note on Monday, May 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. Goldman Sachs Group Inc. assumed coverage on shares of American Renal Associates Holdings in a research note on Monday, May 16th. They issued a “neutral” rating and a $30.00 price objective on the stock. Wells Fargo & Co. assumed coverage on shares of American Renal Associates Holdings in a research note on Monday, May 16th. They set an “outperform” rating on the stock. Finally, Barclays PLC assumed coverage on shares of American Renal Associates Holdings in a research note on Monday, May 16th. They set an “overweight” rating and a $33.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $31.20.

The stock’s market cap is $701.01 million. The company has a 50 day moving average price of $0.00 and a 200-day moving average price of $0.00.

American Renal Associates Holdings (NYSE:ARA) last posted its earnings results on Tuesday, August 9th. The company reported ($0.75) earnings per share (EPS) for the quarter. The company earned $185.60 million during the quarter, compared to analysts’ expectations of $161.50 million. On average, equities analysts forecast that American Renal Associates Holdings Inc. will post $0.96 earnings per share for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.